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a b s t r a c t 
Objectives: Coverage with evidence development (CED) schemes are particularly relevant for medical 
devices (MDs), since clinical evidence is often limited at the time of launch and their long-term (cost- 
) effectiveness heavily depends on how they are adopted into routine clinical practice. The objective of 
this study was to identify and describe the challenges that payers and manufacturers might face when 
assessing the desirability of, choosing the research design for, implementing, and evaluating CED schemes 
for MDs. 
Methods: A systematic literature review was performed on six databases following PRISMA guidelines. 
Two independent reviewers assessed the eligibility of studies based on predefined criteria and extracted 
data from the included articles by using a pre-defined extraction template. The data were synthesised in 
a narrative review. 
Results: The systematic search yielded 4293 articles of which 27 were eligible for inclusion. We identified 
20 challenges that are associated with CED schemes for MDs. Five of these challenges relate directly to 
the characteristics of MDs, and hence are specific to MDs. These challenges concern deciding on whether 
a CED scheme is required, understanding the relevant uncertainties and risks, identifying meaningful out- 
comes, defining an adequate duration for a scheme, and market entry of new technologies. 
Conclusions: Payers and manufacturers of MDs have to address the identified challenges to improve a 
CED scheme’s chance of success. This can be further improved by public sharing of information about 
the outcome of applied schemes and way in which stakeholders have addressed the challenges they faced 
when applying a CED scheme. 
© 2020 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Introduction 
Decisions about the coverage and reimbursement of new health 
technologies are inherently uncertain as, at the time of market 
launch, only limited information is available about their real-world 
performance [1] . Uncertainties typically concern: (1) the safety and 
(relative) clinical effectiveness of a technology in a specified pa- 
tient population, measured by short- and long-term outcomes that 
∗ Corresponding author. 
E-mail address: reckers@eshpm.eur.nl (V. Reckers-Droog). 
are relevant for patients, (2) the value for money of a technology 
and the question whether its reimbursement is considered an effi- 
cient use of available resources, (3) the adoption and diffusion of a 
technology, such as the rate of uptake, disease areas in which the 
technology may be used, possible off-label use, and number of pa- 
tients who may benefit from the technology, and, related to this, 
(4) the budget impact following adoption, i.e. the financial impact 
on the healthcare system, including additional costs and cost sav- 
ings associated with reimbursing the technology [e.g. 1–4 ]. 
These uncertainties may be considerable, especially when 
coverage and reimbursement decisions are taken close to the 
time of product approval (e.g. licensing or Conformité Européenne 
https://doi.org/10.1016/j.hlpt.2020.02.006 
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marking) and when they are inextricably linked to the character- 
istics of the technology, as is often the case for medical devices 
(MDs) [1] . For example, MDs frequently undergo product modi- 
fications that may affect their efficacy and costs, they often have 
multiple applications, and their efficacy may not only depend on 
characteristics of the MD itself but also on the skills and experi- 
ence of those applying a MD in clinical practice [5] . Furthermore, 
uncertainties associated with safety, efficacy, and (cost-) effective- 
ness may be particularly relevant for MDs, as requirements for 
product approval are often less clear and the level of evidence sup- 
porting regulatory and market approval are typically less stringent 
than for pharmaceuticals [5–7] . Although market approval regu- 
lations for MDs will become more stringent in Europe from May 
2020 onwards, the uncertainties associated with coverage and re- 
imbursement of MDs will likely continue to exist as the most strin- 
gent rules will only apply to a small number of MDs, i.e. class III 
(high-risk) MDs, including implants [7 , 8] , and even these rules do 
not eliminate the full range and extent of uncertainty highlighted 
above. 
Traditionally, payers have borne the financial risk of making 
‘wrong’ coverage and reimbursement decisions in the presence of 
uncertainties regarding the real-world performance of health tech- 
nologies. A wrong decision may occur when a health technology 
is reimbursed for which later its original claims on safety, effi- 
cacy, and/or (cost-) effectiveness are not confirmed (type I error) 
or when a technology is not reimbursed but later is shown to be 
more safe and (cost-) effective than relevant comparators used in 
clinical practice (type II error) [6 , 9 , 10] . Regardless of the type of 
error, any wrong decision is undesirable as it will likely always 
lead to loss of benefits to patients (directly or indirectly) and an 
inefficient use of available resources. The risk of making a wrong 
decision and the evidence gap between requirements for regula- 
tory and market approval on the one hand and coverage and re- 
imbursement decisions on the other hand have led to the intro- 
duction and increased use of ‘coverage with evidence development 
(CED)’ schemes [e.g. 2 , 4 , 10 ]. 
CED schemes aim to reduce uncertainties associated with the 
safety, efficacy, and (cost-) effectiveness of health technologies. 
They allow temporary reimbursement of the MD, while more data 
are being collected to enable making a better informed deci- 
sion at a later stage, while sharing the risk of a wrong positive 
(temporary) coverage or reimbursement decision between payers 
and manufacturers during a CED scheme [e.g. 1 , 3 , 6 ]. Thus, they 
avoid uncertain and potentially wrong negative decisions and al- 
low more informed decisions without delaying access to the MD 
for patients. These schemes go under different names in differ- 
ent countries, for example, ‘coverage with evidence development 
schemes’ in the USA, ‘conditionally funded field evaluations’ in 
Canada (Ontario), ‘interim funding schemes’ in Australia, ‘only in 
research (OIR)’ and ‘only with research (OWR)’ in the UK (Eng- 
land/Wales), and ‘conditional reimbursement schemes’ in Belgium 
and the Netherlands [12 , 14] . However, these schemes can all be 
labelled as performance-based risk sharing agreements (PBRSAs), 
i.e. “a plan by which the [clinical] performance of the product is 
tracked in a defined patient population over a specified period of 
time and the level or continuation of reimbursement is based on 
the health and economic outcomes achieved” [1] . Following this 
definition, CED schemes cover schemes that manage utilization in 
the real world and link reimbursement to the performance of a 
health technology as well as schemes that provide additional evi- 
dence with the aim to reduce decision uncertainty [1] . 
Despite the growing interest in CED schemes, they are often 
costly, complex, and challenging [2 , 15] . In response to these chal- 
lenges, ISPOR’s ‘Good Practices for PBRSA Task Force’ formulated 
four good practice questions that need to be addressed when con- 
sidering the use of a CED scheme. These questions concern: (1) the 
desirability of the scheme (as opposed to some other reimburse- 
ment or research arrangement), (2) the choice of research design, 
(3) the approach to implementation, and 4) the method used for 
evaluating the scheme [1] . In principle, the use of CED schemes 
seems particularly relevant to MDs, since clinical evidence is often 
limited at the time of launch and the long-term effectiveness and 
cost-effectiveness is heavily dependent on how they are adopted 
into routine clinical practice. Therefore, the objective of this study 
was to identify and describe the challenges that payers and man- 
ufacturers might face in light of the four good practice questions 
when applying CED schemes for MDs. The results should be of in- 
terest to those who (consider to) apply or design CED schemes for 
MDs and want to improve a scheme’s chance of success. 
Methods 
The systematic review was conducted following the Preferred 
Reported Items for Systematic Review and Meta-Analysis (PRISMA) 
framework [16] . The PRISMA checklist is available as Supplemen- 
tary Material S1. 
Eligibility criteria 
We included studies in the review if they met the follow- 
ing eligibility criteria: (1) the article is a primary study, meta- 
analysis/review, letter, editorial, or note, (2) the article discusses 
(in-depth) the challenges associated with CED schemes for MDs, 
(3) the article is written in English, Italian, Spanish, Portuguese, or 
Dutch, (4) the article is published between 20 0 0 and 2019, and (5) 
the full text is available. 
Following the European Union Directive 2007/47/EC, we defined 
MDs as “any instrument, apparatus, appliance, software, material 
or other article, whether used alone or in combination, together 
with any accessories, including the software intended by its man- 
ufacturer to be used specifically for diagnostic, and/or therapeu- 
tic purposes and necessary for its proper application, intended by 
the manufacturer to be used for human beings for the purpose of 
diagnosis, prevention, treatment, monitoring or alleviation of dis- 
ease”. For our main analysis, we included studies that discussed 
challenges with CED schemes (i) in the specific context of MDs 
and (ii) the context of different types of health technologies if this 
included MDs. To enable a secondary analysis, in which we com- 
pared challenges associated with CED schemes for MDs with those 
for pharmaceuticals, we also included studies that discussed chal- 
lenges with CED schemes solely in the context of pharmaceuticals. 
We excluded studies that merely reported on the characteristics, 
processes, and/or results of applied CED schemes for MDs and that 
discussed challenges solely in the context of financial agreements 
between payer and manufacturer, e.g. price volume agreements, 
budget capping, and discounts. 
Data sources and search strategy 
To identify studies that discussed challenges associated with 
CED schemes for MDs, we conducted a search on the Web of Sci- 
ence (WoS), Pubmed (National Library of Medicine), Embase, and 
Scopus databases in September 2018. We supplemented this with 
a search on the Google and Google Scholar databases in the same 
month and updated this search in January 2019. Furthermore, we 
performed a check on the reference lists of all full texts that we re- 
viewed for eligibility for relevant studies that did not show up in 
our search results. The full electronic search strategy used for WoS 
is available as Supplementary Material S2. This search strategy was 
adapted for use on the other bibliographic and Google databases. 
We did not register a systematic review protocol. 
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Fig. 1. PRISMA flowchart of selection process 
Study selection 
Two reviewers (VRD and CF) independently screened the titles 
and abstracts of all articles based on the predefined eligibility 
criteria. Subsequent to the screening of titles and abstracts, the 
reviewers compared results and resolved disagreements by means 
of dialogue. Articles that were potentially eligible for inclusion 
and those for which the dialogue could not settle disagreement 
between the reviewers were selected for full-text review. The 
reviewers then independently reviewed the full texts, compared 
results, and again resolved disagreement by dialogue. Articles were 
included in the review if they met all eligibility criteria and both 
reviewers agreed on their inclusion. 
Data abstraction 
The same two researchers applied a directed context analysis 
approach to extract data from the selected studies [17] , by using 
a pre-defined extraction template in Microsoft Office Excel. The 
following data were extracted: (1) author(s), (2) year, (3) country, 
(4) type of study, (5) type of health technology, (6) CED scheme for 
MD and the associated medical condition, (7) challenges associated 
with assessing the desirability of a CED scheme, (8) challenges 
associated with choosing the research design for a CED scheme, (9) 
challenges associated with the implementation of a CED scheme, 
(10) challenges associated with the evaluation of a CED scheme, 
and (11) ‘other’ types of challenges associated with a CED scheme 
for MDs, where items 7–10 relate to challenges associated with the 
four good practice questions described in the Introduction section 
and item 11 relates to challenges that fall outside the scope of 
these questions [1] . The data were synthesised in a narrative 
review [18] . 
Although we excluded studies that discussed challenges with 
CED schemes for pharmaceuticals from our main analysis, we also 
extracted the data from these studies in order to examine the sim- 
ilarities and differences between challenges associated with CED 
schemes for MDs and pharmaceuticals. 
Results 
Search results 
The database search yielded a total of 4293 unique records; 
4258 records were yielded from WoS, Pubmed, Embase, and 
Scopus, and 35 from Google and Google Scholar. The screening of 
titles and abstracts resulted in the exclusion of 4196 records. The 
full-text review resulted in the exclusion of another 70 records. 
The main reasons for exclusion were merely reporting on the 
characteristics, processes, and/or results of applied CED schemes 
for MDs (n = 39) and discussion of challenges solely in the context 
of pharmaceuticals (n = 22). The remaining 27 articles met all 
eligibility criteria and were included in the review. Fig. 1 presents 
the PRISMA flowchart of the selection process. 
Study characteristics 
Table 1 presents an overview of the general characteristics of 
the included articles. Of the 27 studies included in the review, 
6 reported on challenges with CED schemes in the specific con- 
text of MDs and 21 on challenges with CED schemes in the con- 
text of different types of health technologies, including MDs. Most 
studies focused on one or more CED schemes applied in the USA 
(n = 10), followed by one or more European countries (n = 9), Aus- 
tralia (n = 6), and Canada (n = 6). A total of 16 studies discussed 
the challenges in the context of 55 existing CED schemes for MDs. 
Most of these schemes were applied in Canada (Ontario) (n = 13), 
followed by the USA (n = 11), UK (n = 9), Australia (n = 5), the 
Netherlands (n = 5), Germany (n = 5), France (n = 3), Belgium 
(n = 3), and Spain (n = 1). 
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Table 1 
General characteristics of the included articles 
# Author(s) [ref] Year Country of focus Type of Study 
Type of health 
technology a 
CED scheme(s) for MDs and associated medical 
condition b 
1 Tunis and Pearson [25] 2006 USA Theoretical All technologies ICDs for the prevention of sudden cardiac death in 
high-risk patients, Balloon angioplasty plus carotid 
stenting for patients with carotid artery disease, 
FDG-PET scan for diagnosis of dementia and 
various cancer types 
2 Hutton et al. [26] 2007 NS Theoretical All technologies NS 
3 Lindsay et al. [27] 2007 USA Case study MDs ICDs for the prevention of sudden cardiac death in 
high-risk patients, FDG-PET scan for various cancer 
types 
4 Carbonneil et al. [14] 2009 Australia, Belgium, 
Canada (Ontario), UK 
(England/Wales), 
Germany, Spain, USA 
Systematic review; 
Survey; Interviews 
All technologies Belgium: DBS, Endovascular treatment of 
abdonimal aneurysms, DES for diabetic patients, 
Cochlear implants; Canada (Ontario): PET scan, 
DES, cardiac CT angiography; France c : 
intensity-modulated radiation therapy, extracranial 
stereotactic radiotherapy; TAVI; Germany: 
screening for skin cancer; Spain: PET scan; USA: 
Cochlear implants, ICDs, PET scan 
5 Dhalla et al. [28] 2009 UK Survey All technologies HealOzone for treatment of tooth decay, 
Endovascular stent insertion for intracranial 
atherosclerotic disease, Soft-palate implant for 
simple snoring 
6 O’Malley et al. [6] 2009 Australia Case study MDs PillCam® Capsule Endoscopy for the evaluation of 
obscure gastrointestinal bleeding 
7 Goeree et al. [29] 2010 Canada (Ontario) Case study; Theoretical MDs and surgical 
procedures 
DES for patients with different medical conditions 
8 Menon et al. [30] 2010 Australia, Canada 
(British Columbia, 
Ontario, and Alberta), 
UK, USA 
Consensus statement All technologies NS 
9 Mohr and Tunis [24] 2010 USA Case studies All technologies Carotid artery stenting, Haemodialysis, FDG-PET for 
diagnosis of dementia and various cancer types, 
ICDs, Cochlear implant, Long-term oxygen therapy, 
Artificial heart, Sleep Apnoea, SCS for patients with 
chronic back and leg pain, Magnetic resonance 
guided focused ultrasound for the treatment of 
uterine fibroids (pilot) 
10 Stafinski et al. [2] 2010 NS Review All technologies Australia: EVAR for treatment of abdominal aortic 
aneurysm, DBS for patients with Parkinson’s 
disease no longer responsive to pharmaceutical 
therapy, PET scan for various cancer types; Canada 
(Ontario): EVAR for treatment of abdominal aortic 
aneurysm, DES for patients with coronary artery 
disease, PET scan for various cancer types, 
diagnosis of solitary pulmonary nodule diagnosis, 
and patients with left ventricular dysfunction for 
whom revascularisation or cardiac transplantation 
was considered, EP for patients with refractory 
cutaneous T-cell lymphoma, MDCTA for diagnosis 
of coronary artery disease, ICDs for prevention of 
sudden cardiac death in patients with coronary 
heart disease, PVP for patients with benign 
prostatic hyperplasia, HBOT for treatment of 
chronic, non-healing, ulcers of the lower limb for 
patients with diabetes mellitus, NWPT (VAC 
system) for patients with chronic pressure wounds 
of the pelvic region; The Netherlands: SCS for 
patients with chronic non-oncological pain; USA; 
carotid artery angioplasty and stenting for the 
prevention of stroke in patients with carotid artery 
disease; PET scan for diagnosis of dementia and 
various cancer types, ICDs for prevention of sudden 
cardiac death in patients with life-threatening 
cardiac dysfunction, Long-term (home) oxygen 
treatment for patients with COPD, Artificial hearts 
for patients with severe biventricular end-stage 
heart disease who are not transplant candidates 
11 Trueman et al. [31] 2010 NS Summary of conference 
presentations; Review 
All technologies Canada (Ontario): DES 
12 Levin et al. [32] 2011 Canada (Ontario) Case studies All technologies DES, EVAR, 64-slide CT angiography, PET scan for 
various cancer types, EP, Insulin infusion pumps in 
the management of insulin-dependent type 2 
diabetes 
13 Mortimer et al. [33] 2011 Australia, UK, USA Theoretical All technologies Australia: DBS for patients in Parkinson’s disease, 
TUNA 
( continued on next page ) 
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Table 1 ( continued ) 
# Author(s) [ref] Year Country of focus Type of Study Type of health 
technology a 
CED scheme(s) for MDs and associated medical 
condition b 
14 Relyea-Chew [34] 2011 USA Case studies All technologies PET scan for diagnosis of 
dementia/neurodegenerative diseases and various 
cancer types 
15 Claxton et al. [22] 2012 NS; UK 
(England/Wales) 
Review; Case studies All technologies Canada: PET scan; USA: ICD, PET scan; UK 
(England/Wales) d : Prostheses for primary total hip 
replacement, Hearing aid technology, Metal on 
metal hip resurfacing for patients with hip disease, 
Photodynamic therapy for (age-related) macular 
degeneration, Carmustine implants for patients 
with glioma, SCS for patients with (chronic 
neuropathic or ischaemic) pain, Cochlear implants 
for patients with hearing impairment, 
Endovascular stent-grafts for patients with 
abdominal aortic aneurysm 
16 Walker et al. [35] 2012 NS Theoretical All technologies NS 
17 Bishop and Lexchin 
[36] 
2013 Australia, Canada, UK, 
USA 
Interviews All technologies NS 
18 Garrison et al. [1] 2013 NS Case studies; 
Theoretical; Taxonomy 
All technologies USA: PET scan for various cancer types, 
Percutaneous transluminal angioplasty and 
stenting for prevention of a second stroke, SCS for 
failed back surgery syndrome 
19 Brügger [12] 2014 Australia, Belgium, 
Canada (Ontario), 
France, Germany, The 
Netherlands, Sweden, 
Switzerland, USA 
Review; Case studies; 
Interviews 
All technologies Australia: HBOT for patients with non-diabetic 
ulcers; Canada (Ontario): DES, PET scan; Germany: 
PET scan for colorectal cancer, Balneo-phototherapy 
for patients with psoriasis, VAC therapy for chronic 
wounds, Brachytherapy for patients with prostate 
cancer; The Netherlands: Radiofrequency 
denervation for patients with chronic non-specific 
low back pain, Intra-arterial 
thrombolysis/thrombectomy in a stroke unit, Renal 
denervation for patients with treatment-resistant 
hypertension, Transluminal endoscopic step-up 
approach in patients with infected pancreatic 
necrosis; USA: PET scan, Artificial hearts, TAVI, 
Cochlear implant, FDG-PET scan for diagnosis of 
dementia 
20 Foster et al. [37] 2014 USA Commentary MDs FDG-PET scan for patients with dementia 
21 Launois et al. [38] 2014 NS Theoretical; Taxonomy All technologies NS 
22 Martelli and van den 
Brink [39] 
2014 France Theoretical MDs NS 
23 Drummond [13] 2015 NS Theoretical All technologies NS 
24 Garrison et al. [40] 2015 USA Review; Survey; 
Interviews 
All technologies NS 
25 Kanavos et al. [23] 2017 NS Theoretical; Taxonomy All technologies NS 
26 Rothery et al. [19] 2017 NS Theoretical MDs NS 
27 van de Wetering et al. 
[15] 
2017 The Netherlands DCE All technologies NS 
COPD, chronic obstructive pulmonary disease; CT, computerised tomography; DBS, deep brain stimulation; DCE, discrete choice experiment; DES, drug-eluding stents; EECP, 
enhanced external counterpulsation; EP, extracorporeal photopheresis; EU, Europe; EVAR, endovascular aneurysm repair; FDG-PET, fluorodeoxyglucose - positron emission 
tomography; HBOT, hyperbaric oxygen therapy; HTA, health technology assessment; ICD, implantable cardioverter-defibrillator; MD, medical device; MDCTA, multidetector 
computed tomographic angiography; NICE, National Institute for Health and Care Excellence; NPWT, negative pressure wound therapy; NS, Not Specified; PET, positron 
emission tomography; PVP, photo selective vaporisation of the prostate; SCS, spinal cord stimulation; TAVI, transcatheter aortic valve implantation; TUNA, transurethral 
needle ablation; UK, United Kingdom; USA, United States of America; VAC, vacuum-assisted closure system 
a All technologies are including MDs. 
b The associated medical condition is presented if specified by the authors. 
c Recommended by national HTA agency, but scheme not initiated. 
d Recommended by NICE. 
Challenges associated with CED schemes for MDs 
We extracted information on 17 challenges from the included 
studies that were associated with assessing the desirability, choos- 
ing the research design, implementation, evaluation, and ‘other’ 
types of challenges with CED schemes for MDs. In particular, these 
17 challenges concern: (1) deciding on whether a CED scheme is 
desirable, (2) understanding the relevant uncertainties and risks, 
(3) lengthy and complex negotiations, (4) defining the decision 
problem, (5) data requirements, (6) identifying meaningful out- 
comes, (7) defining an adequate duration for a scheme, (8) market 
entry of new technologies during a scheme, (9) obtaining fund- 
ing, (10) obtaining informed consent, (11) quality of the data, 
(12) deciding on when a scheme is considered successful, (13) 
withdrawing a technology, (14) lack of transparency, (15) lack of 
governance, (16) stakeholder involvement, and (17) ethical issues. 
Table 2 presents a description of each of these challenges. A full 
overview of the extracted challenges, including those extracted 
from studies discussing the challenges solely in the context of CED 
schemes for pharmaceuticals, is available as Supplementary Mate- 
rial S3. 
These challenges apply to some extent to all CED schemes for 
different types of technologies; however, five relate directly to the 
characteristics of MDs, and hence are specific to MDs. Most of 
these specific challenges were discussed by Rothery et al. (2017) 
and relate to deciding on whether a CED scheme is required, 
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Table 2 
Challenges associated with CED schemes for MDs a 
# Challenge Description 
Desirability 1 Deciding on whether 
a CED scheme is 
required 
Whether CED schemes are recommended depends on both the characteristics of the technology (whether it is 
expected to have a positive net benefit, whether evidence can be generated following reimbursement, and whether 
there would be a cost in reversing the decision at a later data) and the range of authority of the purchaser (whether 
they can delay a decision or review it at later date, whether they can negotiate price, and whether they can ensure 
that research is actually conducted) [35] ; 
Generally, there is a lack of criteria and formal guidelines that can help decide whether a CED scheme can help 
reduce uncertainty and should be initiated [12 , 28 , 39] ; 
The question of whether or not further research is worthwhile requires some assessment of how uncertain a 
decision based on expected cost-effectiveness might be, what the consequences are likely to be if an incorrect 
decision is made, and what a technology that has been subjected to a CED scheme is displacing [22] ; 
There is a close link between the value of a MD, the value of further research to reduce uncertainty and the price of 
the MD. These links can offer incentives for manufacturers to price accordingly and decide whether there is 
sufficient value from further evaluative research. The value of additional research can be informed through VOI 
analysis [19]. However, VOI analysis may be difficult to apply in specific cases and a formal guideline may help 
decide whether research in a particular area is practical and likely to reduce uncertainty [28] . This should be 
enhanced, in particular by clearly stating the selection criteria for MDs that may benefit from such approaches [39] ; 
There is a concern that CED schemes could stifle or slow innovation by creating a disincentive to develop new 
products for conditions for which the evidence base is not well developed or by raising the evidentiary standards 
[24,41] ; 
CED schemes may have the unintended effect of lowering industry investment in evidence development and 
shifting research costs to public fund holders [33] ; 
There is a concern that manufacturers use CED schemes as a mechanism to secure beneficial formulary placement, 
gain market share, and increase patient compliance. Manufacturers may be reluctant to take on the risk of a CED 
scheme when they cannot predict how their product will be used in the real-world population [40] . 
2 Understanding the 
relevant uncertainties 
and risks 
There are challenges in assessing risks upfront due to uncertainties in the real-world performance of a technology 
and further research is unlikely to be able to resolve all uncertainty [31,33] ; 
Some uncertainties cannot be reduced by further research and may resolve by other changes occurring over time. 
For example, the effective price of the technology and/or its comparators may change. The price plays a key role in 
determining the value of the technology, but it also affects the level of uncertainty by changing the likelihood of 
making an incorrect decision and the value of further research [19] . Other uncertainties that cannot easily be 
resolved by further research may concern previously unrecognised adverse effects that emerge in the long term and 
changes in market conditions that might cause the price of the technology to drop in the future [13] ; 
One of the complexities associated with the evaluation of MDs is the fact that any decision about the adoption of 
the MD will interact with the ability to gather more evidence and may affect future commercial developments of 
the technology [19] ; 
There is a group of concerns relating to the introduction of additional uncertainty for manufacturers in terms of 
expected returns, which may have the opposite effect of dis-incentivising additional data collection, the advantage 
competitors may take of data collected by the manufacturer, and related to this is the problem of free-riding [23] . 
3 Lengthy and complex 
negotiations 
Defining the study design is often lengthy and complex, and it may be difficult to reach contractual agreement 
[32,40] ; 
Deciding on the point in the product life cycle at which a technology should be assessed is a contentious issue and 
various stakeholders may have different views on the technologies that require further study, the questions that 
need to be answered, and the necessary methods for answering those questions. It requires the creation of working 
groups made up of key stakeholders and opinion leaders who are involved in designing the study questions and 
methods from the beginning of the process [25,26] ; 
There is protocol development, sample size and site determination, case report form development, contracts with 
sites and investigators and dealing with multiple ethics boards submissions, therefore, study initiation is often 
subject to contractual and legal delays [32] . 
Research design 4 Defining the decision 
problem 
The decision problem is rarely stated explicitly and this creates the risk that the study design does not address the 
decision problem or is not designed to feasibly address that problem [30] ; 
The research design that is most appropriate depends on the nature and type of the uncertainty that the CED 
scheme is trying to address, e.g. uncertainty about whether the medical product or service will be used in the right 
patients or uncertainty at launch about clinical or economic outcomes [42] . 
5 Data requirements A formal guideline for CED schemes should be accompanied by a clear statement regarding what study design and 
data are required to reduce uncertainty [45] . Requirements are often not specified and laws can be unclear at this 
point [39] ; 
The study design that is required to answer questions of evidence development is often not clearly defined, 
especially concerning the need for RCTs or observational/not experimental designs [31] ; 
For the establishment of registries, there are generally no guidelines available [6] ; 
The design of a study should not take place when the decision is made over who should pay for the study as this 
may impose restrictions [22] . 
6 Identifying 
meaningful outcomes 
Outcome measures should be clear, measurable, objective, realistically achievable (in relation to the duration of the 
scheme), and relevant [1] ; 
It is important to be certain that the outcomes of interest are largely influenced by the technology concerned [13] ; 
Manufacturers and payers may shy away from agreements in disease areas where there are many different 
treatment paradigms or the relevant outcome is an intermediary outcome, because it can be challenging to 
attribute the outcome to the product in question. There is also a risk for manufacturers with being responsible for 
outcomes when they cannot control the way a technology is used [40] ; 
Uncertainty about the efficacy of a MD and the learning or training required to achieve the desired efficacy can 
result in adverse consequences on patient outcomes and lead to an ineffective use of healthcare resources [19] ; 
When questionnaires for data collection are designed by physicians, they may not be ideal for use in an economic 
analysis [6] ; 
In some cases, the ‘right’ outcomes may not identified until the scheme is implemented, resulting in failure to 
capture the data needed to reduce the decision-making uncertainty [2] . 
( continued on next page ) 
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7 Defining an adequate 
duration for a scheme 
Designing the necessary clinical research, getting funding, and implementing a scheme in a time frame that is 
consistent with the needs of clinicians, patients, and other decision makers is challenging [25] ; 
With a typical three- to five-year political cycle, there is often a tension between research and political needs [29] ; 
Short-term schemes are not desirable given the considerable investment in evidence development, while long-term 
deals are also not desirable given the costs and risks involved [40] ; 
The unique characteristics associated with MDs, such as rapid incremental innovation, learning effects, and upfront 
irrecoverable costs all present a challenge for the timing of reimbursement decisions and the value of waiting until 
additional evidence is conducted to support the technology [19] ; 
In view of the pace of technological changes in healthcare, a CED scheme of more than three years may be of 
limited relevance for MDs [26,43] . This is because the kinds of policy questions that such studies inform have the 
habit of changing, for example, as other technologies become available for the same patient group [13] . 
8 Market entry of new 
technologies 
The information generated by research will not be valuable indefinitely as new and more effective interventions 
may become available and make the information no longer relevant for future clinical practice [19] ; 
Market access of incremental MD innovations and new technologies may make existing ones obsolete or change 
their cost-effectiveness [26,33] ; 
Rapid approval of new entrants may result in a disincentive for manufacturers to invest in further research that 
would reduce uncertainties about MDs efficacy [19] ; 
MDs that enter the market during a CED scheme may not be included in the scheme, and hence reports may be 
based on evidence from only one MD [6] . 
Implementation 9 Obtaining funding The costs associated with CED schemes can be substantial and a barrier to establishing a viable and cost-effective 
scheme [1,28,29,36,40,44] ; 
CED schemes are perceived to have high transaction costs and be difficult to execute, particularly given the 
fragmented payer system with patient movement across plans, as well as the current lack of data infrastructure that 
limits feasibility and, to some extent, interest in measuring long-term outcomes [40] ; 
It may take years before funding is ensured and then there may still not be sufficient funding to generate the 
evidence needed to reduce uncertainties and meet the HTA agency and decision makers requirements [14,22,25] ; 
Lack of experience with CED schemes, staff turnover, billing requirement complexity, and inconsistency of 
nonresearch and research requirements may add up to significantly more time and effort than anticipated, at times 
for studies with no funding for administration [37] ; 
Some have suggested establishing public-private partnerships between payers and manufacturers, while others have 
stressed the importance of locating publicly funded research organizations who may be perceived as neutral and, 
therefore, better able to provide control over research design and data, and manage vested interests [2,31] . 
10 Obtaining informed 
consent 
Identifying and counselling potential participants and obtaining informed consent requires considerable effort and 
patients may decline to participate or may prematurely withdraw. The need for frequent reconsent, e.g. when 
regulations change mid study, should be taken into account [37] ; 
If patients or physicians withhold consent, the patients’ data will not be used for research, but it will still be stored, 
e.g. in a registry, and may still be reimbursed under a CED scheme [27] . 
Evaluation 11 Quality of the data It may be difficult to obtain consensus amongst stakeholders about what is considered an acceptable quality of 
evidence [22]; 
After coverage or reimbursement is obtained for a technology, there may be a lack of incentive, e.g. for 
manufacturers, to collect the data [25] ; 
There is the risk that research may not happen, does not answer the initial questions, does not feed back into 
decision making and the technology is funded anyway, or does not deliver the evidence while the funding cannot 
be stopped [12] ; 
Evidence generated may not meet the quality criteria or be sufficient for making coverage decisions, e.g. when 
relying on observational data alone [2,12,14] ; 
The accuracy, reliability, and completeness of the data, e.g. when submitted to a registry, often depends on 
physicians and they may not always have the necessary time to complete the forms accurately [5,17,28] ; 
Physicians are not (always) paid for data collection and reporting, which may affect the quality of the data, and 
there may substantial missing data, e.g. due to loss to follow-up in registries, which may lead to bias [6] ; 
There is an additional burden to monitoring a CED scheme and of collecting and analysing the data collected as part 
of a CED scheme. This may affect the quality of the data [26] ; 
For the success of a scheme, it is imperative that payers and manufacturers trust the data and clear agreements on 
data validation and analysis are important to create this trust [40] . 
12 Deciding on when a 
CED is considered 
successful 
There still is little evidence to support the claimed benefits of CED schemes and the extent to which some of the 
challenges involved in CED scheme implementation impact on the final outcome [23] ; 
It is not clear if CED schemes succeed in limiting reimbursement to specific patient subgroups and payers are 
sceptical that CED schemes will reduce costs in the long run [23,24] ; 
As it may not be possible to assess the VOI generated by a CED scheme directly post hoc, there is a need to rely on 
process indicators for assessing a scheme’s success. Such process indicators should relate to the research questions 
relating to the design, implementation and evaluation of the scheme and include the questions, i.e. are the intended 
outcome measures collected, was uncertainty in associated parameter estimation reduced for the outcomes that 
were the focus of the scheme, did the scheme run to budget and time, was the integrity of the design/estimation 
maintained, did the governance arrangements work well, and did the success to underpin a decision with further 
evidence prove successful [1] ; 
Whether the CED scheme has achieved its objectives and can be considered good value from a health system 
perspective is linked to the desirability of the scheme and can be addressed from multiple perspectives: 
manufacturer, patient, payer, provider, and society. A comprehensive evaluation will therefore need to consider 
multiple perspectives [1] ; 
The success of CED schemes when manufacturers are asked to conduct the research will depend on whether the 
authorities are able to establish contractual arrangements as part of a CED scheme, that is, arrangements that can 
be monitored and enforced with credible penalties to ensure that agreed research is conducted and in the way 
intended [22] . 
( continued on next page ) 
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13 Withdrawing a 
technology 
Once a technology is used in practice–even if formally temporary–ending reimbursement may be less feasible than 
initially not reimbursing it, especially when the technology proves to be effective, but not cost-effective [1,15,26] ; 
Decisions to withdraw may cause heated discussions with doctors, patients, and politicians and be followed by a 
public debate in the media [12]; 
Patients may also be more motivated to exert political pressure to secure or maintain coverage of last-line 
treatment for life-threatening illnesses than for preventative or ‘me-too’ interventions. Inertia in clinical practice 
may be a barrier to delisting, particularly for interventions with a long-standing place in both formularies and 
clinical practice. Payers may adopt a passive role and rely upon clinicians to modify their prescribing practice to 
replace inferior interventions with more effective or better-tolerated alternatives as and when they become 
available. Evidence development may be delayed if the default position is to extend funding until the data become 
available [33] . 
Other 14 Lack of transparency There is a general lack of information on CED schemes in the public domain that is attributed to ‘commercial 
confidentiality’. Consequently, payers who consider CED schemes as a potential policy option have little information 
upon which to base a decision [2] ; 
There is little information available on the agreements implemented, their objectives, and evaluation of their 
impact. This prevents cross-country learning and limits the ability of patients to engage with CED processes [23] ; 
Disclosure of the results of previous schemes related to a technology of interest may reduce duplication of effort s. 
Mechanisms for increasing transparency around key components, e.g. objectives, conflicts of interest, data collection 
management, and oversight, of the scheme that respect commercial interests are required to build on previous good 
research practices for specific types of studies [1,2] . 
15 Lack of governance Lack of project management and coordination can be an obstacle for CED schemes and can make it difficult to 
ensure an update of the recommendation following the production of new evidence [12,14,22] ; 
The independence of a scheme from any party with a vested interest in its outcomes should be ensured [30] ; 
Stakeholders may take contradictory positions (also amongst themselves) around where the leadership should rest 
and which stakeholders should be involved in a CED scheme [36]; 
Supervision of the research may create a conflict of interest for a HTA body as they need to keep the image of being 
a helper for a better quality healthcare system [12] . 
16 Stakeholder 
involvement 
The various stakeholders can affect political decisions around the initiation of a CED scheme. For example, 
manufacturers may pressure the initiation of a scheme and conflicts of interest may arise when manufacturers play 
a role in the funding, data collection, and evaluation of a scheme [36] ; 
Patients, generally, have limited opportunities to engage in the development of a scheme and not all patient groups 
are aware of what CED schemes entail [23] ; 
Patient advocacy groups may be unwilling to accept this policy especially if the assessed treatment is considered to 
be safe and efficacious [22] . They may distrust the motives of payers in their effort s to support evidence 
development through coverage, and may assume that the primary objective is cost containment, rather than a 
genuine effort to support early access to innovations and clinical research [24] ; 
There may be significant opposition from the clinical community and compliance with data collection by physicians 
may be weak, e.g. because of lack of staff [11,31] ; 
There is the risk that CED schemes are perceived as a tool for monitoring or controlling physicians, particularly in 
the context of registers on interventional procedures with or without the use of MDs [40] ; 
Compliance with data collection by physicians may be weak and the monitoring of the study poor because of lack 
of clinical staff [12] ; 
The translation of evidence into policy is riddled with political and economic considerations, both the overt political 
process involved in CED and the role of the pharmaceutical industry. The most explicit evidence of relations of 
power comes from the hierarchy of roles in the decision-making process. Political influences play a role in 
determining where the money for CED will come from and where the ultimate decision-making comes from [36] . 
17 Ethical issues CED schemes may be beneficial for future patients, but they can impose significant opportunity costs on current 
patients. Some individuals in the present population may benefit from the research condition because they will also 
be members of the future population. However, this will not be true for all and so the issue of balancing the 
interests of some individuals in the present population against some individuals in the future population remains 
[22] ; 
Various stakeholders, e.g. policy makers and patient groups, have questioned whether it is ethical to restrict access 
to technologies to patients participating in registries and clinical trials, and to withhold a potentially beneficial 
innovation from a subset of patients who cannot, or will not, participate while providing it to another 
[12,22,24,25,31,34] . It is also questioned whether study participation concerns coercion and whether patients’ 
informed consent is valid in this context [24,25,34] ; 
Patient advocacy groups may be unwilling to accept a CED scheme, especially if the treatment has demonstrated 
safety and efficacy [31] ; 
Furthermore, CED schemes may result in inequities as participants in the treatment arm may receive better 
treatment than those in the other arm and those not participating, and treatments may not be available in all 
geographical areas [22,34] . 
AWR, approval with research; CE, Conformité Européenne; CED, coverage with evidence development; FDA, Food and Drug Administration; GRP, good research practice; NICE, 
National Institute for Health and Care Excellence; OIR, only in research; RCT, randomised controlled trial; USA, United States of America; VOI, value of information. 
a For reasons of clarity, we used the term CED scheme in this table, where the author(s) at times used the terms performance-based risk sharing agreement or access 
with evidence development scheme. The original terms used by the author(s) can be found in Supplementary Material S3. The classification of challenges into ‘Desirability’, 
‘Research design’, ‘Implementation’, and ‘Evaluation’ of CED schemes relate to the four good practices questions that were formulated by ISPOR’s ‘Good Practices for PBRSA 
Task Force’ [1] . ‘Other’ relates to challenges that fall outside the scope of these questions. 
understanding the relevant uncertainties and risks, identifying 
meaningful outcomes, defining an adequate duration for a scheme, 
and market entry of new technologies. For example, it may be par- 
ticularly challenging to decide whether a CED scheme is required 
for a MD as the prices of MDs are likely to change over time due to 
rapid incremental MD innovations and market entry of new MDs. 
This may directly impact the uncertainty associated with making 
a wrong coverage or reimbursement decision and the value of 
further research into MDs’ cost-effectiveness. Incremental innova- 
tions, high upfront irrecoverable costs, and market entry of new 
MDs may also result in a disincentive for (individual) manufactur- 
ers to invest in research that would reduce uncertainty about MDs’ 
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efficacy. This may lead to a situation in which research costs shift 
to public fund holders. Furthermore, the changes over time in 
prices of MDs and due to gradual innovations can complicate 
defining an adequate duration for a scheme and this, in turn, may 
impact the identification of and data collection on meaningful out- 
comes. The identification of meaningful outcomes may also be par- 
ticularly challenging for MDs as the outcomes of interest are typ- 
ically not only influenced by the MD, but also by the subsequent 
treatment, e.g. as is the case for diagnostic MDs such as positron 
emission tomography (PET) scans. Furthermore, MDs’ effectiveness 
is not only influenced by characteristics of the MD itself but may 
to a large extent be influenced by the learning or training of physi- 
cians that is required to achieve the optimal effect. The associated 
learning curve of physicians may result in a more modest impact 
on patient outcomes or higher costs during the early use of MDs, 
resulting in a lower cost-effectiveness of MDs when assessed in the 
short run or early in the development phase. 
A qualitative assessment of the similarities and differences be- 
tween challenges associated with CED schemes for MDs and other 
types of technologies, e.g. pharmaceuticals, did not reveal any chal- 
lenges with CED schemes for other types of technologies that do 
not also apply to MDs. However, we identified three challenges 
that were discussed in the context of CED schemes for pharmaceu- 
ticals that were not found in the included studies, yet are also con- 
sidered to be applicable to MDs. The first challenge concerns the 
information asymmetry between payers and manufacturers about 
the potential real-world performance of a technology and the im- 
pact this may have on CED-scheme agreements [20] . The second 
challenge concerns the ex-ante definition of a final decision rule 
based on the gathered information and ‘exit strategy’. It needs 
to be defined when the (cost-) effectiveness and/or safety of a 
technology is deemed to be below expectations or some relevant 
threshold, leading to its withdrawal or a premature termination of 
the CED scheme [11] . Ideally, this would also entail a withdrawal 
implementation plan. The third challenge concerns the economies 
of scale in the management of CED schemes and the difficulties 
small countries may have in applying CED schemes because of the 
associated costs and monitoring mechanisms [20] . 
Discussion 
The objective of this study was to identify and describe the 
challenges that payers and manufacturers might face when as- 
sessing the desirability of, choosing the research design for, im- 
plementing, and evaluating CED schemes for MDs. We identified 
20 distinct challenges that are associated with CED schemes for 
MDs. Most of these challenges are not specific for MDs; how- 
ever, five are, as they relate directly to the characteristics of MDs. 
These challenges concern deciding on whether a CED scheme is 
required, understanding the relevant uncertainties and risks, iden- 
tifying meaningful outcomes, defining an adequate duration for a 
scheme, and market entry of new technologies during the exis- 
tence of a scheme. The majority of studies discussed challenges 
with CED schemes in the context of applied CED schemes for MDs. 
Generally, studies discussed challenges with CED schemes for all 
types of technologies and only few specifically discussed them for 
MDs. Most of the challenges that relate to the characteristics of 
MDs were discussed by Rothery et al. (2017). 
These results suggest that the challenges associated with 
CED schemes for MDs and the relationship between these chal- 
lenges and the characteristics of MDs are infrequently researched. 
Although the many similarities between challenges with CED 
schemes for MDs and other types of technologies, such as phar- 
maceuticals, may have reduced the need for research in this area, 
these results can still be considered remarkable given the consider- 
able decision uncertainty associated with coverage and reimburse- 
ment of MDs and the direct relevance of CED schemes in this con- 
text. Our finding that challenges with CED schemes for MDs are 
infrequently researched is further illustrated by the fact that this, 
to our knowledge, is the first systematic review of the literature 
that focuses specifically on this topic. Although we consider this 
a strength, some limitations also deserve attention. Firstly, CED 
schemes go under many different names and some schemes that 
are applied for MDs may have a confidential nature [12 , 14 , 21] . 
Consequently, we cannot rule out the possibility that there are 
challenges associated with CED schemes for MDs that we have not 
identified and described in our review. We also cannot rule out the 
possibility that there are CED schemes for MDs that are not iden- 
tified and mentioned in our review ( Table 1 ), as we excluded arti- 
cles that merely reported on the characteristics, processes, and/or 
results of applied CED schemes. However, this limitation does not 
affect our main findings. Secondly, we synthesised our results in 
a qualitative rather than a quantitative review. Hence, our review 
does not provide information about the extent to which the char- 
acteristics of MDs impact on the challenges associated with CED 
schemes, nor about the frequency and intensity with which the 
challenges occur in practice. Finally, some of the studies included 
in our review applied a combination of methods to gain insight 
into challenges associated with CED schemes that are not technol- 
ogy specific. For example, Carbonneil et al. (2009), Claxton et al. 
(2012), and Brügger (2014) have supplemented their review of the 
literature with one or more case studies, a survey, and/or inter- 
views with experts. Future research may be aimed at gaining addi- 
tional insight into the challenges specifically associated with CED 
schemes for MDs, for example, by conducting interviews with pay- 
ers who are experienced in applying these schemes. 
Future research may also be aimed at validating and deepen- 
ing the understanding of the identified challenges and examining 
possible differences in (the intensity of) challenges associated with 
CED schemes for different types of MDs, i.e. implantable, diag- 
nostic, and therapeutic devices. Interviews may, for example, also 
provide insight into whether high upfront investment costs pose 
more of a challenge than rapid incremental innovation for CED 
schemes for diagnostic devices such as PET scans. Furthermore, we 
would like to note that the challenges were mainly described from 
the perspective of payers and manufacturers of MDs, even though 
some of the identified challenges with CED schemes directly re- 
late to the role of other stakeholders, such as patients and physi- 
cians. Future research may be aimed at obtaining insight into pos- 
sible additional challenges that are associated with CED schemes 
for MDs, e.g., from the perspective of other stakeholders, that are 
not yet identified and discussed in this review, yet may also be 
considered relevant for those who (intend to) apply CED schemes 
for MDs. 
To improve a CED scheme’s chance of success, it is considered 
important that payers and manufacturers of MDs have insight into 
and address the challenges described in this review. However, the 
challenges associated with evaluating CED schemes for MDs make 
it clear that there is little evidence to support the claimed ben- 
efits of CED schemes [23] . Indeed, studies infrequently report on 
the outcomes of CED schemes and little is known about their im- 
pact on patients’ access to technologies and the reduction of costs 
in the long run [20 , 23 , 24] . Public sharing of information about 
the outcomes of applied schemes may reduce the overlap in CED 
schemes for MDs between countries as, for example, observed for 
the USA, Australia, Canada (Ontario), Germany, and Spain. These 
countries have all applied a CED scheme for PET scans for diagnosis 
of dementia and/or various cancer types. Public sharing of informa- 
tion about the outcome of applied schemes and the way in which 
various stakeholders have addressed the challenges they faced 
when applying (or participating in) CED schemes for MDs may fur- 
ther improve a CED scheme’s chance of success. For example, by 
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increasing cross-country learning, reducing the costs of individual 
schemes, improving the design of future schemes, and increasing 
trust amongst payers that CED schemes are a valuable option. 
Conclusions 
The results of this study indicate that there are at least 20 
challenges that payers and manufacturers might face when apply- 
ing CED schemes for MDs. Some of these challenges are specific 
to MDs, given their distinct characteristics, but many are relevant 
more generally. The MD-specific challenges concern deciding on 
whether a CED scheme is required, understanding the relevant 
uncertainties and risks, identifying meaningful outcomes, defining 
an adequate duration for a scheme, and market entry of new tech- 
nologies. It is considered important that payers and manufacturers 
of MDs are aware of, and where possible proactively address, these 
challenges when considering the use of a CED scheme, also to 
improve its chances of success and final reimbursement decisions. 
Public sharing of information about the outcomes of applied 
schemes and the way in which various stakeholders have ad- 
dressed the challenges they faced when applying (or participating 
in) CED schemes for MDs may further improve their future use and 
contribute to better decision making in health care. 
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